CoChat

VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

Open access
Genovese, Mark C., van Vollenhoven, Ronald F., Pacheco‐Tena, César, Zhang, Yanqiong, Kinnman, Nils · 2016 · Arthritis & Rheumatology
Cited by 128

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective: To assess the efficacy and safety of decernotinib (VX‐509), an oral selective inhibitor of JAK‐3, in patients with rheumatoid arthritis (RA) in whom the response to methotrexate treatment was inadequate. Methods: In this 24‐week, double‐blind, randomized phase IIb study, 358 patients with active RA received either placebo (n = 71) or VX‐509 at dosages of 100 mg/day (n = 71), 150 mg/day (n = 72), 200 mg/day (n = 72), or 100 mg twice daily (n = 72). Primary measures of efficacy at week 12 were the response rate according to the American College of Rheumatology 20% improvement criteria (ACR20) and change from baseline in the Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP). Results: At week 12, the ACR20 response rates were 46.5%, 66.7%, 56.9%, and 68.1% in the groups receiving VX‐509 at dosages of 100 mg/day, 150 mg/day, 200 mg/day, and 100 mg twice daily, respectively, and 18.3% in the placebo group (P < 0.001 for all comparisons). At week 12, the mean change from baseline in the DAS28‐CRP was significantly greater in each VX‐509 group compared with the placebo group (P < 0.001). Improvements were maintained at week 24, as shown by the ACR20, ACR50, and ACR70 response rates and mean change from baseline in the DAS28‐CRP. The most common adverse event in the VX‐509 group was headache (8.7%), and elevated levels of transaminases, lipoproteins, and creatinine were observed. Conclusion: VX‐509 significantly improved the signs and symptoms of RA at weeks 12 and 24 compared with the placebo group when it was administered in combination with methotrexate. Safety signals included infection and increases in liver transaminase and lipid levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.39473

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Janus kinases in immune cell signaling

    Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149 · cited 2×

    “Completed original dosing (n=17) Completed original dosing (n=44) Completed original dosing (n=47) Completed original dosing (n=51) Discontinued (n=13) • Adverse event (6) • Refused further dosing (2) • Lost to follow-up (2) • Did not meet eligibility criteria (1) • Physician decision (1) • Other (1) Discontinued (n=9…”
    Background

Show all 1 references

Cited by

Metadata

Authors
Genovese, M. C., van Vollenhoven, R. F., Pacheco‐Tena, C., Zhang, Y., & Kinnman, N.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2015-12-23
Volume
68
Issue
1
Pages
46-55
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W1916256274
Cited by
128
References
1
FWCI
8.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.